SCHEMBL23869353

SCHEMBL23869353

N#Cc1cccc(-c2cc(-n3c4ccccc4c4cc(-c5ccccc5)ccc43)ncc2-n2c3ccccc3c3cc(-c4ccccc4)ccc32)c1C#N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.39
HIF1A Q16665 1/20 0.39
ALDH1A1 P00352 3/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
SSTR2 P30874 1/20 0.33
GABRG2 P18507 4/20 0.32
GABRB3 P28472 4/20 0.32
GABRA5 P31644 2/20 0.32
GABRA3 P34903 2/20 0.32
CYP11B1 P15538 1/20 0.32
CYP11B2 P19099 1/20 0.32
FLT3 P36888 1/20 0.31
NR3C1 P04150 1/20 0.31
TRPA1 O75762 1/20 0.31
GABRA1 P14867 3/20 0.31
GABRA2 P47869 3/20 0.31
PDE10A Q9Y233 1/20 0.31
CYP1A2 P05177 2/20 0.31
CYP3A4 P08684 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23869366 0.97 SMN1; SMN2 (0.41) SMN1; SMN2HIF1AALDH1A1NPSR1TDP1
SCHEMBL23855961 0.94 NR3C1 (0.34) SMN1; SMN2HIF1AALDH1A1NR3C1TRPA1
SCHEMBL23855891 0.93 SMN1; SMN2 (0.33) SMN1; SMN2HIF1AALDH1A1CYP1A2CYP3A4
SCHEMBL21929062 0.92 ALDH1A1 (0.37) ALDH1A1NPSR1TDP1SSTR2GABRG2
SCHEMBL23869346 0.92 SMN1; SMN2 (0.37) SMN1; SMN2HIF1AALDH1A1GABRG2GABRB3
SCHEMBL21928999 0.88 GABRG2 (0.39) ALDH1A1NPSR1TDP1GABRG2GABRB3
SCHEMBL23856007 0.88 SMN1; SMN2 (0.33) SMN1; SMN2HIF1ANR3C1
SCHEMBL31037700 0.88 SMN1; SMN2 (0.33) SMN1; SMN2HIF1ANR3C1
SCHEMBL23855824 0.88 SMN1; SMN2 (0.33) SMN1; SMN2HIF1ANR3C1
SCHEMBL23855926 0.88 ALDH1A1 (0.38) SMN1; SMN2ALDH1A1NPSR1TDP1CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12029116-B2 Composition of matter for use in organic light-emitting diodes KYULUX, INC. (JP) 2024-07-02 US disclosed
US-12029116-B2 Composition of matter for use in organic light-emitting diodes KYULUX, INC. (JP) 2024-07-02 US disclosed
US-20210305517-A1 COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES KYULUX, INC. (JP) 2021-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12029116-B2 Composition of matter for use in organic light-emitting diodes OPRD1, DRD1, DRD3 SMN1; SMN2 3726/4885HIF1A 4659/4885ALDH1A1 812/4885
US-20210305517-A1 COMPOSITION OF MATTER FOR USE IN ORGANIC LIGHT-EMITTING DIODES OPRD1, DRD1, DRD3 SMN1; SMN2 3726/4885HIF1A 4659/4885ALDH1A1 812/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.